Literature DB >> 6285930

Effects of propranolol and a number of its analogues on sodium channels.

J C Matthews, J K Baker.   

Abstract

To assess the relative contributions that the sodium channel blocking activity of propranolol may play in a variety of its therapeutic applications, its effects were examined in vitro with a sodium channel specific 22Na+ uptake system, using rat brain membranes. Propranolol inhibited 22Na+ uptake in the rat brain membrane preparation by acting as a competitive inhibitor of the binding of the sodium channel opening agent veratridine, with an IC50 for this action of 6.5 microM. This is approximately one order of magnitude higher in concentration than that necessary for expression of the beta-adrenergic antagonism of propranolol. The binding of propranolol and its action to block sodium channels were demonstrably different from those of the neurotoxins tetrodotoxin and saxitoxin. Propranolol had effects on sodium channels that are similar, although not identical to those of the local anesthetics procaine and lidocaine. The concentrations of propranolol and a number of its analogues which produced 50% inhibition of 22Na+ uptake (IC50 values ranging from 4 to greater than 100 microM) were similar to the concentrations of these same analogues which were required to produce negative inotropic and antiarrythmic effects (ED40) on isolated rabbit atria [D. O. Rauls and J. K. Baker, J. med. Chem, 22, 81 (1979)]. These effects showed correlations of 0.945 and 0.936, respectively, with the 22Na+ uptake inhibition. It is concluded from this information that a substantial proportion of the negative inotropic and antiarrythmic effects of propranolol is due to its action on sodium channels.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6285930     DOI: 10.1016/0006-2952(82)90668-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Propranolol inhibits nonexocytotic noradrenaline release in myocardial ischemia.

Authors:  G Richardt; U Lumpp; M Haass; A Schömig
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990 Jan-Feb       Impact factor: 3.000

2.  DL-propranolol inhibits the vascular changes in the rat carotid body induced by long-term hypoxia.

Authors:  J M Pequignot; S Hellström; C Johansson
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

3.  Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.

Authors:  David Lindenbach; Corinne Y Ostock; Karen L Eskow Jaunarajs; Kristin B Dupre; Christopher J Barnum; Nirmal Bhide; Christopher Bishop
Journal:  J Pharmacol Exp Ther       Date:  2011-03-14       Impact factor: 4.030

4.  Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3.

Authors:  Larissa Fabritz; Dierk Damke; Markus Emmerich; Susann G Kaufmann; Kathrin Theis; Andreas Blana; Lisa Fortmüller; Sandra Laakmann; Sven Hermann; Elena Aleynichenko; Johannes Steinfurt; Daniela Volkery; Burkhard Riemann; Uwe Kirchhefer; Michael R Franz; Günter Breithardt; Edward Carmeliet; Michael Schäfers; Sebastian K G Maier; Peter Carmeliet; Paulus Kirchhof
Journal:  Cardiovasc Res       Date:  2010-01-28       Impact factor: 10.787

5.  Direct and indirect effects of ciguatoxin on guinea-pig atria and papillary muscles.

Authors:  R J Lewis; R Endean
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-11       Impact factor: 3.000

6.  Dopamine-induced amylase secretion from rat parotid salivary gland in vitro: an effect mediated via noradrenergic and cholinergic nerves.

Authors:  F Hata; H Ishida; E Kondo
Journal:  Br J Pharmacol       Date:  1986-11       Impact factor: 8.739

Review 7.  Genetics of inherited primary arrhythmia disorders.

Authors:  Danna A Spears; Michael H Gollob
Journal:  Appl Clin Genet       Date:  2015-09-18

8.  Pharmacological separation of early afterdepolarizations from arrhythmogenic substrate in DeltaKPQ Scn5a murine hearts modelling human long QT 3 syndrome.

Authors:  G Thomas; M J Killeen; A A Grace; C L-H Huang
Journal:  Acta Physiol (Oxf)       Date:  2007-10-31       Impact factor: 6.311

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.